Pharmacopeia, Inc. (ACCL) (Prev: PCOP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacopeia, Inc. (ACCL) (Prev: PCOP)

ACCL 4.028

+0.7%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Lang who wrote ()	10/15/1998 1:00:00 PM
From: kinkblot	Read Replies (1) of 179

Patent recently issued to Schering Corporation and Pharmacopeia, Inc.: patents.ibm.com U.S. Patent #5,801,175 "Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases", issued Sept. 1, 1998. . . . . . . . . . . ABSTRACT: Novel compounds of Formula [Figure] are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the above formula to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. . . . . . . . . . . This appears to be the first U.S. patent issued based on work performed under one of PCOP's collaborations. The patent application was published in October 1996 via the Patent Cooperation Treaty process, which allows inventors to secure international filing rights. It was a continuation-in-part filed in September 1996 of a patent originally filed in April 1995. The agreement with Schering-Plough was signed in December 1994 to identify and optimize lead compounds against targets in the fields of asthma and cancer. WT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next